BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2026)

BioNexus Gene Lab has reported Cost of Revenue for 9 years, with the latest figure at $23632.0 in Q1 2026.

• Quarterly Cost of Revenue fell 98.68% year-over-year to $23632.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 42.86% YoY) and the FY2025 annual result came in at $6.3 million, down 22.89% from the prior year.
• Cost of Revenue retreated to $23632.0 in Q1 2026 per BGLC's latest filing, from $487743.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.7 million in Q1 2022 and troughed at $23632.0 in Q1 2026.
• A 5-year average of $1.9 million and a median of $2.2 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue gained 12.24% in 2025, then plunged 98.68% in 2026.
• Over 5 years, Cost of Revenue stood at $2.5 million in 2022, then declined by 19.75% to $2.0 million in 2023, then grew by 10.37% to $2.2 million in 2024, then slumped by 77.98% to $487743.0 in 2025, then slumped by 95.15% to $23632.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $23632.0, $487743.0, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.